澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; pregelatinised maize starch; povidone; magnesium stearate; titanium dioxide; hypromellose; triacetin - vttack is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation. this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 40 mg/ml - suspension, powder for - excipient ingredients: titanium dioxide; sodium benzoate; citric acid; colloidal anhydrous silica; sodium citrate dihydrate; sucrose; xanthan gum; flavour - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; pregelatinised maize starch; povidone; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: sulfobutyl betadex sodium - vfend is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. *prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: arginine; sodium hydroxide; dilute hydrochloric acid; hydroxypropylbetadex - voriconazole is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp. and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

以色列 - 英文 - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - voriconazole - powder for concentrate for solution for infusion - voriconazole 200 mg/vial - voriconazole - vortimal is a broad spectrum, triazole antifungal agent and is indicated as follows:- treatment of invasive aspergillosis.- treatment of candidaemia in non-neutropenic patients.- treatment of fluconazole-resistant serious invasive candida infections (including c. krusei).- treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vortimal should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients

以色列 - 英文 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 200 mg - voriconazole - treatment of: - invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei),- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

以色列 - 英文 - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - voriconazole - film coated tablets - voriconazole 50 mg - voriconazole - treatment of:- invasive aspergillosis, - fluconazole-resistant serious invasive candida infections (including c. krusei)- serious fungal infections caused by scedosporium spp. and fusarium spp.- vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. - treatment of candidemia in non neutropenic patients.- prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: nitrogen; water for injections; sulfobutyl betadex sodium - voriconazole ? aft is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.